Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Collaborating with pharma/biotech clients worldwide, Vetter supports products from preclinical development through global market supply. Through its U.S. and European facilities, Vetter Development Service provides state-of-the-art support for early-stage products, with seamless transfer at Phase III to Vetter Commercial Manufacturing for large-scale production. The company offers state-of-the-art technology and innovative processes to promote product quality and maximize API yield.

Resources for every stage of growth.

Vetter's full portfolio of services includes dedicated resources for both clinical development and commercial manufacturing. In addition, we provide expert packaging technologies and solutions tailored to your product's specific market needs:

Vetter Development Service (VDS) supports your drug-development projects, from inception to market launch. Our Chicago facility, along with our existing sites, provides clinical manufacturing from preclinical development through Phase II, with scale-up and transfer to our commercial manufacturing facilities. The Chicago site is the first to use Bosch's new fully automated vial filler, designed specifically for early-stage, high-value biopharmaceuticals. VDS fills clinical trial materials under strict aseptic and GMP standards. Thanks to state-of-the-art technology and innovative processes, we help increase your API yield.

Early planning can help save costs: Together, we work with you to develop the appropriate delivery system for your drug, starting in early development. In addition to matching all components to your product's specifications, we replicate commercial manufacturing processes in our laboratories, which can prevent surprises when your drug reaches market production. Once products reach Phase III, we provide seamless transfer to our large-scale manufacturing facilities in Europe for late-stage and commercial production. Simultaneous activities, coupled with expertise and foresight, reduce time to market. To help prolong your success, Vetter also offers support on product lifecycle management, which ideally begins in the preclinical phase and becomes an integral part of the drug development process.

Planning for success.
Preclinical through Phase III is a pivotal and unpredictable period for new molecules. Vetter Development Service helps smooth the path to clinic with dedicated support for key stages of development, testing, clinical manufactur…

Filling your potential
Precise manufacturing. Creative thinking. It takes both to succeed in a competitive marketplace. Vetter Commercial Manufacturing supports your injectable with more than 25 years of expertise in high-quality, state-of-the-art as…

Packaging matters
Material compatibility. Patient convenience. Market differentiation. There are many factors to consider in the selection of your primary and secondary packaging materials. Which ones matter most to your compound’s performance…

Setting up a multi-product, clinical manufacturing fill-and-finish operation differs significantly from traditional commercial manufacturing. Find out how these operations differ and more in an important case study presentation during the Biopharmaceutical Development & Production (BDP) week.

You need to know! Vetter experts will discuss their experience and knowledge about new syringe systems, disposable isolators, contamination control, and aseptic production at the 2014 Annual Pharma-Congress in Dusseldorf, March 25 & 26.